A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2019
Price : $35 *
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 28 Aug 2019 Planned End Date changed from 15 Mar 2025 to 14 Jun 2025.
- 28 Aug 2019 Planned primary completion date changed from 15 Aug 2023 to 16 Jun 2024.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology